Printer Friendly

PRP, INC. GRANTED U.S. PATENT FOR PLATELET DERIVATIVE; EARLY RESEARCH SUGGESTS POTENTIAL AS SAFE AND CONVENIENT ALTERNATIVE TO FRESH PLATELETS

 WATERTOWN, Mass., March 2 /PRNewswire/ -- PRP, Inc. announced today that the United States Patent and Trademark Office has awarded the company a broad-based patent (U.S. No.5,185,160) covering a virus-free, freeze-dried platelet derivative and its use in transfusion to control bleeding. The patent establishes for PRP a position as a leader in the development of innovative substitutes for human blood products.
 The invention is based on a discovery by PRP that the outer membrane of human platelets can be isolated, heat treated, freeze-dried into a powder and stored for at least one year while maintaining the ability to control bleeding. The heat treatment step eliminates the risk of transmitting viruses such as hepatitis and HIV. The extended shelf-life of the product should allow for predictable supply for transfusion and may substantially reduce the waste of valuable blood products at hospitals and blood banks. Fresh platelets become out-dated after three to five days in storage and are unfit for use in transfusion. PRP's lead product based on the patented technology is called IPM.
 "The award of this U.S. patent covering the company's core technology is a significant milestone for PRP, and will provide a strong proprietary position as we move forward with the clinical development and commercialization of IPM," commented Francis C. Chao, M.D., Ph.D., PRP president and chief executive officer. "In preclinical models of platelet deficiency, IPM appears safe and effective in restoring platelet function." Dr. Chao noted that platelet transfusion is used in a variety of medical situations including the treatment of patients with low platelet counts after undergoing surgery, chemotherapy or radiation therapy.
 The patent awarded to PRP affords the company broad commercial protection as it covers not only the virus-free, freeze-dried platelet derivative and its use, but also the methods for producing the product from fresh or out-dated platelets. The company has filed related patent applications internationally covering its core technology.
 PRP, Inc. of Watertown, Mass., is a biopharmaceutical company engaged in the discovery, development and commercialization of human therapeutics based on platelets.
 -0- 3/2/93
 /CONTACT: Dr. Francis C. Chao, president & CEO of PRP, Inc., 617-924-5550; Lynne H. Brum of Feinstein Partners Inc., 617-577-8110, for PRP, Inc./


CO: PRP, Inc. ST: Massachusetts IN: MTC SU: PDT

CH -- NE001 -- 1777 03/02/93 08:58 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 2, 1993
Words:386
Previous Article:NATIONAL COMPUTER SYSTEMS, INC. ANNOUNCES QUARTERLY CASH DIVIDEND
Next Article:DIGITAL'S DECpc MT SERIES BOASTS FEATURE-PACKED DESKSIDE POWER IN "MICRO-TOWER" DESKTOP DESIGN
Topics:


Related Articles
PRP, INC. COMPLETES $2.0 MILLION PRIVATE PLACEMENT; ADVANCES CLINICAL PROGRAM FOR HUMAN BLOOD PLATELET SUBSTITUTE
YAMANOUCHI/PDL ANTI-PLATELET ANTIBODY INHIBITS PLATELET COAGULATION WITH LITTLE INCREASE IN BLEEDING
Company With Proprietary Technology For Safer Blood Products Adopts New Name
VITEX PLAS+(R)SD Provides Safer Alternative to Plasma.
Cerus Corporation Announces Third Quarter Results.
Cerus Corporation Announces Fourth Quarter And Year-End Results.
Cerus Phase 3 Intercept Platelet System Trials Move Forward on Favorable Monitoring Board Report.
Cerus U.S. Phase 3 Trial of Platelet Pathogen Inactivation System Moves Forward on Monitoring Board Report.
Reliability of the thrombin-generation assay in frozen-thawed platelet-rich plasma.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters